Company profile: Ikonisys
1.1 - Company Overview
Company description
- Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
Products and services
- Ikoniscope20max: A high-volume microscope assembly with an automated slide loader processing up to 160 FISH slides, architected for unattended batch analysis and accelerated throughput in FISH workflows
- Ikoniscope20: A fully-automated microscope system that handles slide scanning, real-time image capture, and analysis, scanning up to 2,000,000 cells per slide for rare-cell detection
- OncoFISH bladder: A FISH-based microscopy application that scans and analyzes cells from urine samples to detect urothelial carcinomas using FISH probes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ikonisys
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
Accession Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accession Therapeutics company profile →
AbilityPharma
HQ: Spain
Website
- Description: Provider of oncology drug discovery and development of therapeutics targeting cell membranes to address unmet needs. Focused on lung and pancreatic cancers, it develops ABTL0812, a first-in-class autophagy inducer in phase 2b trials for metastatic pancreatic cancer. Includes R&D on cytotoxic autophagy, funding partnerships, and FDA/EMA Orphan Drug Designations for pancreatic and biliary cancers and pediatric neuroblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbilityPharma company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ikonisys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ikonisys
2.2 - Growth funds investing in similar companies to Ikonisys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ikonisys
4.2 - Public trading comparable groups for Ikonisys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →